Modified herpes virus joins forces with immunotherapy to attack head and neck tumors
NCT ID NCT07010120
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This study tests a combination of three treatments—immunotherapy (tislelizumab), targeted therapy (afatinib), and a modified herpes virus (lysogenic HSV)—given before surgery for head and neck squamous cell carcinoma. The goal is to see if this approach safely shrinks tumors and improves outcomes. Participants are adults aged 18 to 70 with locally advanced, surgically removable head and neck cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tislelizumab, Afatinib, and lysogenic HSV virus
What this could lead to
If successful, this combination could shrink head and neck tumors before surgery, potentially improving survival and reducing the need for more aggressive treatments.
What could go wrong
This is an early-phase trial with only 29 participants, so results may not apply broadly. The modified herpes virus and drug combination may cause side effects like immune reactions or organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Radiation Oncology
Chengdu, Sichuan, 610000, China